1. Introduction {#sec1-molecules-24-02850}
===============

*Urena lobata*, belonging to the family Malvaceae, is an annually shrubby herbage widely distributed around the world, particularly in the tropical and subtropical areas of Asia, South America, and Africa \[[@B1-molecules-24-02850]\]. This plant is also known as Caesar weed, Congo jute, and Bachita, the local name varies from region to region. In Africa, the leaves and flowers of *U. lobata* could be eaten as food during famine time and the bast fiber of *U. lobata* is used as cordage material \[[@B2-molecules-24-02850]\]. More interestingly, *U. lobata* is also commonly used in folk medicines for the treatment of diabetes, abdominal colic, malaria, gonorrhea, dysentery, fever, rheumatism, and edema \[[@B3-molecules-24-02850],[@B4-molecules-24-02850]\]. Pharmacological studies indicated that the extract of *U. lobata* showed significant antibacterial, antihyperglycemic, antinociceptive, antidiarrheal, anti-inflammatory, and wound healing activities \[[@B5-molecules-24-02850],[@B6-molecules-24-02850],[@B7-molecules-24-02850]\]. In China, *U. lobata* is also named "Ditaohua," which is dominantly distributed in the south of China, such as Guangxi, Yunnan, and Guizhou provinces and clinically used to treat pathological leucorrhea and gonorrhea \[[@B8-molecules-24-02850]\]. Promoted by these significant activities, great efforts have been made to clarify the bioactive constituents of *U. lobata* leading to the separation and elucidation of flavonoids, phenylethyl glycosides, lignans, coumarins, and triglycerides \[[@B1-molecules-24-02850],[@B9-molecules-24-02850],[@B10-molecules-24-02850],[@B11-molecules-24-02850],[@B12-molecules-24-02850],[@B13-molecules-24-02850]\]. In our previous report, 16 megastigmane glycosides were identified from *U. lobata* \[[@B14-molecules-24-02850]\]. As an ongoing study, four new lignan glycosides, urenalignosides A--D (**1**--**4**) together with 12 known ones (**5**--**16**) were obtained from *U. lobata* ([Figure 1](#molecules-24-02850-f001){ref-type="fig"}). Herein, the isolation and structural elucidation of the new compounds, as well as their inhibitory effects on NO production on LPS-stimulated RAW264.7 macrophage cells, are described.

2. Results {#sec2-molecules-24-02850}
==========

The 95% EtOH extracts of *U. lobata* were suspended in H~2~O and extracted successively with petroleum ether (PE), EtOAc, and *n*-BuOH. The *n*-BuOH soluble fraction was separated by D~101~ macroporous adsorption resin, silica gel, and Sephadex LH-20 column chromatography and semi-preparative HPLC to afford four new lignan glycosides (**1**--**4**) together with 12 known ones (**5**--**16**) ([Figure 1](#molecules-24-02850-f001){ref-type="fig"}).

Compound **1** was obtained as a colorless powder. Its molecular formula was assigned as C~30~H~40~O~15~ due to the presence of a \[M − H\] ^−^ ion at *m/z* 639.2282 (calcd for C~30~H~39~O~15~, 639.2294) in the HRESIMS spectrum ([Figure S1](#app1-molecules-24-02850){ref-type="app"}), which was also supported by the ^13^C-NMR data ([Table 1](#molecules-24-02850-t001){ref-type="table"}). The IR spectrum of **1** showed the absorption bands contributing to hydroxy group (3385 cm^−1^), benzene ring (1615 and 1518 cm^−1^), and ester carbonyl (1735 cm^−1^) group. The NMR spectra of **1** ([Figures S2 and S3](#app1-molecules-24-02850){ref-type="app"}) showed the presence of two 1,3,4,5-tetrasubstituted benzene moieties \[*δ*~H~ 6.78 (2H, s, H-2,6), 6.80 (2H, s, H-2′,6′). *δ*~C~ 134.1 (C-1), 105.2 (C-2,6), 149.4 (C-3,5), 136.3 (C-4); 133.6 (C-1′), 104.8 (C-2′,6′), 149.3 (C-3′,5′), 136.4 (C-4′)\], two oxygenated methines \[*δ*~H~ 5.12 (1H, d, *J* = 8.0 Hz, H-7), 4.98 (1H, d, *J* = 9.0 Hz, H-7′). *δ*~C~ 85.6 (C-7), 84.2 (C-7′)\], two *sp*^3^ methines \[*δ*~H~ 2.75 (1H, m, H-8), 2.45 (1H, m, H-8′). *δ*~C~ 52.7 (C-8), 51.1 (C-8′)\], two oxygenated methylenes \[*δ*~H~ 4.36 (1H, overlapped, H-9′a) and 3.72 (1H, dd, *J* = 12.0, 5.0 Hz, H-9′b); 4.09 (1H, dd, *J* = 10.0, 5.5 Hz, H-9a) and 3.80 (1H, dd, *J* = 10.0, 4.5 Hz, H-9b). *δ*~C~ 69.3 (C-9), 64.8 (C-9′)\], and four methoxyl groups \[*δ*~H~ 3.93 (12H, s), *δ*~C~ 56.9\]. Comparison of the above NMR data with those of icariol A~2~ \[[@B15-molecules-24-02850]\], a lignan previously isolated from *Epimedium sagittatum*, revealing the presence of an icariol A~2~ moiety in **1**. In addition, signals due to an acetyl group \[*δ*~H~ 1.95 (3H, s), *δ*~C~ 20.7, 172.8\] and a glucopyranosyl moiety were also observed in the NMR spectra of **1**. The anomeric proton was presented at *δ*~H~ 4.36 (1H, d, *J* = 8.0 Hz), corresponding to the carbon at *δ*~C~ 104.6 assigned by HSQC experiment, and the relatively large coupling constant (*J* = 8.0 Hz) of the anomeric proton suggested that the glucopyranosyl moiety was in *β* configuration. Given that naturally occurring glucose is D-form, and limited by the small amount of **1**, we tentatively determined the glucopranosyl moiet in **1** was in D-form. In the HMBC spectra of **1**, the correlations between the anomeric proton *δ*~H~ 4.36 (1H, d, *J* = 8.0 Hz, H-1′′) and C-9 (*δ*~C~ 69.3) confirmed that the glucopyranosyl moiety was linked at C-9 ([Figure 2](#molecules-24-02850-f002){ref-type="fig"}). The acetyl group was linked at C-9′ determined by the HMBC correlation between H-9′ and the carbonyl carbon (*δ*~C~ 172.8). All the protons and carbons were unambiguously assigned ([Table 1](#molecules-24-02850-t001){ref-type="table"}) by ^1^H-^1^H COSY, HSQC, and HMBC experiments ([Figures S4--S6](#app1-molecules-24-02850){ref-type="app"}).

The relative configuration of **1** was determined by NOESY spectrum ([Figure S7](#app1-molecules-24-02850){ref-type="app"}), which showed the NOE correlations of H-7/H-8′ and H-7′/H-8. The CD spectra ([Figure S8](#app1-molecules-24-02850){ref-type="app"}) of **1** showed the positive Cotton effect at 246 nm suggested that both C-7 and C-7' were in *R* configuration \[[@B16-molecules-24-02850],[@B17-molecules-24-02850]\], and thus the configuration of C-8, and C-8' were assigned as 8*S*, 8'*S*. Accordingly, the structure of **1** was determined as shown in [Figure 1](#molecules-24-02850-f001){ref-type="fig"}, named as *urenalignoside A*.

Compound **2** was obtained as colorless powder. Its molecular formula was assigned as C~27~H~38~O~13~ by the \[M + HCOO\]^--^ ion at *m/z* 615.2284 (calcd for C~28~H~39~O~15,~ *m/z* 615.2294) in the HRESIMS spectrum ([Figure S9](#app1-molecules-24-02850){ref-type="app"}), which was also supported by the ^13^C-NMR -NMR data ([Table 1](#molecules-24-02850-t001){ref-type="table"}). The NMR spectra of **2** ([Figures S10 and S11](#app1-molecules-24-02850){ref-type="app"}) showed the presence of a 1,3,4-trisubstituted \[*δ*~H~ 7.28 (1H, d, *J* = 1.5 Hz, H-2), 6.83 (1H, d, *J* = 8.0 Hz, H-5), 6.96 (1H, dd, *J* = 8.0, 1.5 Hz, H-6). *δ*~C~ 130.8 (C-1), 113.3 (C-2), 148.7 (C-3), 147.1 (C-4), 115.5 (C-5), 122.1 (C-6)\] and a 1,3,4,5-tetrasubstituted benzene moieties \[*δ*~H~ 6.53 (2H, s, H-2′,6′). *δ*~C~ 135.1 (C-1′), 106.7 (C-2′,6′), 154.3 (C-3′,5′), 139.9 (C-4′)\], two oxygen-bearing methines \[*δ*~H~ 5.31 (1H, d, *J* = 3.0 Hz, H-7), 4.23 (1H, m, H-8). *δ*~C~ 77.7 (C-7), 86.8 (C-8)\], two oxygen-bearing methylenes \[*δ*~H~ 3.61 (2H, t, *J* = 6.4 Hz, H-9′), 3.16 (2H, m, H-9). *δ*~C~ 62.8 (C-9′), 61.4 (C-9)\], two methylenes \[*δ*~H~ 2.67 (2H, t, *J* = 7.5 Hz, H-7′), 1.86 (2H, m, H-8′). *δ*~C~ 33.4 (C-7′), 35.4 (C-8′)\], and three methoxy groups \[*δ*~H~ 3.89 (3H, s, 3-OCH~3~), 3.74 (6H, s, 3′,5′-OCH~3~). *δ*~C~ 56.4 (3, 3′, 5′-OCH~3~)\]. Comparison of the above-mentioned NMR data with those of 1-(4′-hydroxy-3′-methoxy-phenyl)-2-\[4′′-(3-hydroxypropyl)-2′′,6′′-dimethoxyphenoxy\] propane-1,3-diol, a lignan previously isolated from *Bursera tonkinensis* \[[@B18-molecules-24-02850]\], suggested the occurrence of an 8-*O*-4′-neolignan moiety in **2**. In addition, signals due to a glucopyranosyl moiety were also observed in the NMR spectra of **2**. The relatively large coupling constant (*J* = 7.5 Hz) of the anomeric proton resonated at *δ*~H~ 4.23 (1H, d, *J* = 7.5 Hz, H-1′′) suggested the glucopyranosyl moiety was in *β* configuration. The linkage of the glucopyranosyl moiety was determined at C-7 by the HMBC correlation between the anomeric proton and C-7 ([Figure 2](#molecules-24-02850-f002){ref-type="fig"}). Unambiguous assignments of the protons and carbons ([Table 1](#molecules-24-02850-t001){ref-type="table"}) were achieved by ^1^H-^1^H COSY, HSQC, HMBC, and NOESY experiments ([Figures S12--S15](#app1-molecules-24-02850){ref-type="app"}).

It has been well reported that the relative configurations of C-7 and C-8 could be solved by the analysis of the coupling constant between H-7 and H-8. Regularly, a relatively small coupling constant (*J* = 3--4 Hz) between H-7 and H-8 defines the *erythro* configurations of C-7 and C-8, while a relatively large coupling constant (*J* = 6--8 Hz) give rise to the *threo* configurations of C-7 and C-8 \[[@B19-molecules-24-02850],[@B20-molecules-24-02850],[@B21-molecules-24-02850],[@B22-molecules-24-02850],[@B23-molecules-24-02850],[@B24-molecules-24-02850]\]. Accordingly, the stereochemistry of C-7 and C-8 in **2** were assigned as *erythro* according to the small coupling constant (*J* = 3.0 Hz) between H-7 and H-8. The positive Cotton effect at 233 nm in the CD spectrum ([Figure S16](#app1-molecules-24-02850){ref-type="app"}) of **2** suggested that the configuration of C-8 was *S* \[[@B22-molecules-24-02850],[@B24-molecules-24-02850],[@B25-molecules-24-02850],[@B26-molecules-24-02850]\], and thus the configuration of C-7 was determined as *R*. Therefore, the structure of **2** namely *urenalignoside B* was elucidated as shown in [Figure 1](#molecules-24-02850-f001){ref-type="fig"}.

Compound **3** was obtained as a colorless powder, with a molecular formula of C~25~H~34~O~13~ determined by the presence of a \[M − H\]^--^ ion at *m/z* 541.1920 (calcd for C~25~H~33~O~13~, *m/z* 541.1927) in the HRESIMS spectrum ([Figure S17](#app1-molecules-24-02850){ref-type="app"}). The NMR data of **3** ([Figures S18--S23](#app1-molecules-24-02850){ref-type="app"}) is comparable to those of **2**, except the absence of one methoxy group in **3**. In the HMBC spectrum of **3**, the correlation between the anomeric proton \[*δ*~H~ 4.93 (1H, *J* = 7.5 Hz, H-1′′)\] of the glucopyranosyl moiety and the C-3' of the aglycon demonstrated that the glucopyranosyl moiety was linked at C-3' in **3** ([Figure 2](#molecules-24-02850-f002){ref-type="fig"}). The large coupling constant (*J* = 8.5 Hz) between H-7 and H-8 suggested that the C-7 and C-8 were in *threo* orientation. The negative Cotton effect at 233 nm in the CD spectrum ([Figure S24](#app1-molecules-24-02850){ref-type="app"}) of **3** suggested that the configuration of C-8 was *R* \[[@B23-molecules-24-02850],[@B24-molecules-24-02850]\], and thus the configuration of C-7 was 7*R*. Therefore, the structure of **3** namely *urenalignoside C* was determined as shown in [Figure 1](#molecules-24-02850-f001){ref-type="fig"}.

Compound **4** was obtained as a colorless powder, with a molecular formula of C~27~H~38~O~13~ by the \[M − H\]^--^ ion *m/z* 569.2258 (calcd for C~27~H~37~O~13~, *m/z* 569.2240) in the HRESIMS spectrum ([Figure S25](#app1-molecules-24-02850){ref-type="app"}). Comparison of the NMR data of **4** ([Figures S26--S31](#app1-molecules-24-02850){ref-type="app"}) with those of **2** revealed that these two compounds share a highly similar skeleton, except the significantly deshielded chemical shift of C-9′ (*δ*~C~ 69.2; ∆*δ*~C~ + 6.3), suggesting that the *O*-glucopyranosyl moiety was linked at C-9′ in **4**, but not like that at C-7 in **2**. The deduction was confirmed by HMBC correlation between the anomeric proton \[*δ*~H~ 4.32 (1H, *J* = 8.0 Hz, H-1′′)\] and C-9′ ([Figure 2](#molecules-24-02850-f002){ref-type="fig"}). The relatively large coupling constant (*J* = 7.0 Hz) between H-7 and H-8 suggested that the C-7 and C-8 were in *threo* orientation. The absolute configuration of C-8 was assigned as *S* based on the positive Cotton effect at 233 nm presented in the CD spectrum ([Figure S32](#app1-molecules-24-02850){ref-type="app"}) of **4** \[[@B22-molecules-24-02850],[@B24-molecules-24-02850],[@B25-molecules-24-02850],[@B26-molecules-24-02850]\], and thus the configuration of C-7 was assigned as *S*. Accordingly, the structure of **4** namely *urenalignoside D* was determined as shown in [Figure 1](#molecules-24-02850-f001){ref-type="fig"}.

By comparison of their spectroscopic and specific rotation data with those of the known compounds, the remaining 11 compounds were identified as (7*R*,8*R*)-*threo*-4,9,9'-trihydroxy-3,3',5'-trimethoxy-8-*O*-4'-neolignan-7-*O*-*β*-[d]{.smallcaps}-glucopyranoside (**5**) \[[@B21-molecules-24-02850]\], rourinoside (**6**) \[[@B22-molecules-24-02850]\], (7*R*,8*R*)-*threo*-guaiacylglycerol-8-*O*-4'-sinapyl ether-7-*O*-*β*-[d]{.smallcaps}-glucopyranoside (**7**) \[[@B23-molecules-24-02850]\], (7*S*,8*R*)-*erythro*-4,9,9'-trihydroxy-3,3'-dimethoxy-8-*O*-4'-neolignan-7-*O*-*β*-[d]{.smallcaps}-glucopyranoside (**8**) \[[@B24-molecules-24-02850]\], (7*S*,8*S*)-*threo*-4,9,9'-trihydroxy-3,3'-dimethoxy-8-*O*-4'-neolignan-7-*O*-*β*-[d]{.smallcaps}-glucopyranoside (**9**) \[[@B24-molecules-24-02850]\], (--)-(7*R*,8*S*)-4,7,9,3′,9′-pentahydroxy-3-methoxy-8-*O*-4′-neolignan-9′-*O*-*β*-[d]{.smallcaps}-glucopyranoside (**10**) \[[@B25-molecules-24-02850]\], (7*S*,8*S*)-4,7,9,3',9'-pentahydroxy-3-methoxyl-8-*O*-4'-neolignan-4-*O*-*β*-[d]{.smallcaps}-glucopyranoside (**11**) \[[@B26-molecules-24-02850]\], (7*S*,7'*S*,8*R*,8'*R*)-icariol A~2~-9-*O*-*β*-[d]{.smallcaps}-glucopyranoside (**12**) \[[@B16-molecules-24-02850]\], (7*S*,7'*S*,8*S*,8'*S*)-icariol A~2~-4-*O*-*β*-[d]{.smallcaps}-glucopyranoside (**13**) \[[@B27-molecules-24-02850]\], lyoniresinol-9'-*O*-*β*-[d]{.smallcaps}-glucopyranoside (**14**) \[[@B28-molecules-24-02850]\], (−)-isolariciresinol 4-*O*-*β*-[d]{.smallcaps}-glucopyranoside (**15**) \[[@B29-molecules-24-02850]\], and cedrusin-4'-*O*-*β*-[d]{.smallcaps}-glucopy ranoside (**16**) \[[@B30-molecules-24-02850]\], respectively. Compounds **2**--**11** and **16** are neolignans which are classified as a subgroup of lignan family \[[@B31-molecules-24-02850]\].

3. Materials and Methods {#sec3-molecules-24-02850}
========================

3.1. General Experimental Procedures {#sec3dot1-molecules-24-02850}
------------------------------------

Optical rotations were obtained on a Rudolph Autopol IV automatic polarimeter (Hackettstown, NJ, USA). IR spectra were recorded on a Thermo Nicolet Nexus 470 FT-IR spectrophotometer (Madison, WI, USA) with KBr pellets. UV spectra were obtained using a Shimadzu UV-2450 spectrophotometer (Tokyo, Japan). NMR spectra were recorded on a Varian INOVA-500 spectrometer (Palo Alto, CA, USA) operating at 500 MHz for ^1^H-NMR and 125 MHz for ^13^C-NMR. HRESIMS was recorded on an LCMS-IT-TOF system, fitted with a Prominence UFLC system and an ESI interface (Shimadzu, Kyoto, Japan). Silica gel (200--300 mesh, Qingdao Marine Chemical Inc., Qingdao, China), LiChroprep RP-C~18~ gel (40--63 μm, Merck, Germany), D~101~ m acroporous adsorption resin (Qingdao Marine Chemical Inc., Qingdao, China) and Sephadex LH-20 (Qingdao Marine Chemical Inc., Qingdao, China) were used for open column chromatography (CC). HPLC was performed on a ShimadzuLC-20AT pump system (Shimadzu Corporation, Tokyo, Japan), equipped with an SPD-M20A photodiode array detector monitoring at 254 nm. A semi-preparative HPLC column (YMC-Pack C~18~, 250 × 10 mm, 5 μm) was employed for the isolation. TLC was performed using GF~254~ plates (Qingdao Marine Chemical Inc., Qingdao, China).

3.2. Plant Material {#sec3dot2-molecules-24-02850}
-------------------

*Urena lobata* L. was collected in Guangxi Province, People's Republic of China, in September 2013. The plant material was authenticated by one of the authors (P.F. Tu) and a voucher specimen (DTH2013029) was deposited at the Modern Research Center for Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China.

3.3. Extraction and Isolation {#sec3dot3-molecules-24-02850}
-----------------------------

The air-dried *U. lobata* (13.6 kg) were refluxed with 95% EtOH for three times (3 × 180 L, each for 1 h). After removing the solvent under reduced pressure, the residue (1.35 kg) was suspended in water (6 L), and partitioned with petroleum ether (3 × 6 L), EtOAc (5 × 6 L), and *n*-BuOH (3 × 6 L), successively. The *n*-BuOH-soluble fraction (158 g) was subjected to D~101~ macroporous adsorption resin column and eluted with H~2~O--EtOH (100:0, 90:10, 50:50, 20:80, 0:100) to yield five fractions (Fr. 1-5). Fr. 2 (20 g) and Fr. 3 (40 g) were combined and subjected to silica gel chromatography and eluted with a stepwise gradient of EtOAc-MeOH-H~2~O from 30:2:1 to 5:2:1 to give five subfractions (Subfr. A--E). Subfr. B (8 g) was chromatographed on a Sephadex LH-20 column and eluted with MeOH to give six subfractions (Subfr. B1--B6). Subfr. B3 (1 g) was chromatographed on a silica gel column and eluted with gradient of CH~2~Cl~2~--MeOH (12:1, 10:1, 8:1, 5:1, 1:1, v/v) to give seven subfractions (Subfr. B3a--B3g). Subfr. B3d (0.2 g) was purified by semipreparative HPLC using 27% aqueous MeCN as the mobile phase to afford compound **7** (2.1 mg, *t*~R~ 34.5 min). Subfr. B3g (0.1 g) was applied to semi-preparative HPLC using 25% aqueous MeCN to obtain two compounds **8** (3.1 mg, *t*~R~ 23.0 min) and **9** (4.2 mg, *t*~R~ 48.5 min). Subfr. B4 (4 g) was subjected to RP-C~18~ open column and eluted with a stepwise gradient of MeOH--H~2~O (1:4, 1:3, 1:2, 2:3, 1:0, v/v), to afford five fractions (Subfr. B4a--Subfr. B4e). Subfr. B4a (1.2 g) was applied to semi-preparative HPLC using 25% aqueous MeCN to give compound **1** (1.2 mg, *t*~R~ 28.5 min). Subfr. B4c (1.1 g) was further separated by ODS column chromatography and eluted with MeOH--H~2~O (1:19→1:3) to obtain six fractions (Subfr. B4c1--B4c6). Subfr. B4c4 was repeatedly separated and purified by semi-preparative HPLC (27% aqueous MeCN) to give two fractions Subfr. B4c4-1 (25.3 mg, *t*~R~ 40.0 min), Subfr. B4c4-2 (7.4 mg, *t*~R~ 49.0 min), and five compounds **3** (3.0 mg, *t*~R~ 44.5 min), **4** (2.1 mg, *t*~R~ 30.0 min), **5** (2.5 mg, *t*~R~ 36.0 min), **12** (7.5 mg, *t*~R~ 23.5 min), and **13** (2.5 mg, *t*~R~ 27.5 min). Subfr. B4c4-2 was purified by semi-preparative HPLC (30% aqueous MeOH) to give compounds **10** (1.8 mg, *t*~R~ 55.5 min) and **11** (2.0 mg, *t*~R~ 57.0 min). Subfr. B4c5 was applied to semi-preparative HPLC using 10% aqueous MeOH to give compounds **2** (2.5 mg, *t*~R~ 32.0 min), **6** (3.2 mg, *t*~R~ 37.0 min), **14** (2.1 mg, *t*~R~ 43.5 min), **15** (1.8 mg, *t*~R~ 54.0 min), and **16** (1.2 mg, *t*~R~ 55.5 min).

*Urenalignoside A* (**1**): Colorless powder, $\left\lbrack \mathsf{\alpha} \right\rbrack_{D}^{25}$: −45.7 (*c* 0.1, MeOH); UV *λ* (log *ε*): 208 (4.49), 317 (4.31), 383 (3.91) nm; IR (KBr) ν~max~: 3385, 2921, 1735, 1615, 1518, 1462, 1428, 1367, 1331, 1217, 1114, 1076, 1036 cm^−1^; ^1^H and ^13^C-NMR data (see [Table 1](#molecules-24-02850-t001){ref-type="table"}); negative-ion HRESIMS: *m*/*z* 639.2282 \[M -- H\]^--^ (calcd for C~30~H~39~O~15~, 639.2294).

*Urenalignoside B* (**2**): Colorless powder, $\left\lbrack \mathsf{\alpha} \right\rbrack_{D}^{25}$: −64.0 (*c* 0.1, MeOH); UV *λ* (log *ε*): 202 (4.14),226 (4.25), 277 (3.37), 298 (2.63), 317 (2.48), 329 (2.40), 341 (2.43), 348 (2.38) nm; IR (KBr) ν~max~: 3423, 2926, 1630, 1384, 1253, 1119, 1076, 1037 cm^−1^; ^1^H and ^13^C-NMR data (see [Table 1](#molecules-24-02850-t001){ref-type="table"}); negative-ion HRESIMS: *m*/*z* 615.2284 \[M + HCOO\]^−^ (calcd for C~28~H~39~O~15~, 615.2294).

*Urenalignoside C* (**3**): Colorless powder, $\left\lbrack \mathsf{\alpha} \right\rbrack_{D}^{25}$: −52.4 (*c* 0.1, MeOH); UV *λ* (log *ε*): 212 (4.58), 285 (4.00) nm; IR (KBr) ν~max~: 3389, 2968, 2923, 2852, 1739, 1610, 1456, 1431, 1366, 1259, 1228, 1216, 1174, 1111, 1028 cm^−1^; ^1^H and ^13^C-NMR data (see [Table 1](#molecules-24-02850-t001){ref-type="table"}); negative-ion HRESIMS: *m*/*z* 541.1920 \[M − H\]^−^ (calcd for C~25~H~33~O~13~, 541.1927).

*Urenalignoside D (***4***)*: Colorless powder, $\left\lbrack \mathsf{\alpha} \right\rbrack_{D}^{25}$: −54.0 (*c* 0.1, MeOH); UV *λ* (log *ε*): 207 (4.62), 263 (4.70), 316 (4.23) nm; IR (KBr) ν~max~: 3739, 3716, 3660, 3430, 2956, 2924, 2853, 1717, 1592, 1514, 1488, 1455, 1428, 1383, 1367, 1230, 1157, 1125, 1023 cm^−1^; ^1^H and ^13^C-NMR data (see [Table 1](#molecules-24-02850-t001){ref-type="table"}); negative-ion HRESIMS: *m*/*z* 569.2258 \[M − H\]^−^ (calcd for C~27~H~37~O~13~, 569.2240).

3.4. Biological Assays {#sec3dot4-molecules-24-02850}
----------------------

The murine macrophage RAW264.7 cell line was purchased from Peking Union Medical College (PUMC) Cell bank (Beijing, China), and was cultured in DMEM supplemented with 10% Fetal Bovine Serum, 100U/mL penicillin G and 100 μg/mL streptomycin, in a humidified 5% CO~2~ at 37 °C. Cell viability was evaluated using MTT assay. The NO concentration was detected by the Griess method. Briefly, RAW264.7 macrophage cells were seeded into 96-well plates at a density of 5 × 10^4^ cells/well and stimulated with 0.5 μg/mL LPS (Sigma, St. Louis, MO, USA) in the presence or absence of test compounds. After incubation for 24 h at 37 °C, treated RAW264.7 macrophage cells were incubated with 100 μL MTT solution (0.5 mg/mL in medium) for another 4 h at 37 °C, subsequently, the supernatants were removed and residues were dissolved using 150 μL DMSO for each well; 50 μL of cell-free supernatant was mixed with 100 μL of Griess reagent containing equal volumes of 2% (*w/v*) sulfanilamide in 5% (*w/v*) phosphoric acid and 0.2% (*w/v*) *N*-(1-naphthyl) ethylenediamine solution to measure nitrite production. The absorbance was detected at 540 nm using a microplate reader (Thermo, Waltham, MA, USA). Compared with a calibration curve prepared using NaNO~2~ standards. The experiments were performed in triplicate. quercetin was conducted as a positive control. All the compounds were prepared as stock solutions in DMSO (final solvent concentration less than 0.3% in all assays).

3.5. Bioactivity Evaluation {#sec3dot5-molecules-24-02850}
---------------------------

Compounds **1**--**16** were evaluated for their inhibitory effects on the NO production in LPS-stimulated RAW 264.7 macrophage cells. Quercetin was used as a positive control (IC~50~ = 7.2 ± 0.2 μM). Compounds **2**--**4**, **6**, **7**, **10**, and **11** exhibited weak inhibitory activity against NO production with IC~50~ values of 90.4 ± 3.2 μM, 74.3 ± 1.8 μM, 88.1 ± 2.2 μM, 98.4 ± 3.6 μM, 97.5 ± 2.6 μM, 97.7 ± 3.5 μM, 25.5 ± 1.2 μM, respectively.

**Sample Availability:** Samples of the compounds **1**--**16** are available from the authors.

The following materials are available online: HRESIMS and NMR spectra data of compounds **1--4** as supporting information.

###### 

Click here for additional data file.
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###### 

Data of compounds **1**--**4** (500 MHz for ^1^H and 125 MHz for ^13^C, CD~3~OD, *J* in Hz).

  ------------------------------------------------------------------------------------------------------------------------------------------------
  No.              1 ^a^                    2 ^a^   3 ^a^                  4 ^a^                                                           
  ---------------- ------------------------ ------- ---------------------- ------- ---------------------- ------- ------------------------ -------
  1                                         134.1                          130.8                          133.5                            133.3

  2                6.78, s                  105.2   7.28, d, (1.5)         113.3   7.01, d, (1.5)         111.6   7.08, d, (1.5)           112.2

  3                                         149.4                          148.7                          149.0                            148.5

  4                                         136.3                          147.1                          147.5                            147.0

  5                                         149.4   6.83, d, (8.0)         115.5   6.77, d, (8.5)         116.1   6.78, d, (8.0)           115.7

  6                6.78, s                  105.2   6.96, dd, (8.0, 1.5)   122.1   6.88, dd, (8.0, 1.5)   121.1   6.94, dd, (8.0, 1.5)     121.0

  7                5.12, d, (8.0)           85.6    5.31, d, (3.0)         77.7    4.97, d, (8.5)         75.0    5.12, d, (7.0)           74.4

  8                2.75, m                  52.7    4.23, m                86.8    4.01, m                89.7    4.16, m                  88.3

  9                3.80, dd, (10.0, 4.5)\   69.3\   3.16, m\               61.4\   3.69, m\               61.3\   3.62, m\                 62.1\
                   4.09, dd, (10.0, 5.5)                                                                                                    

  1′                                        133.6                          135.1                          140.0                            133.3

  2′               6.80, s                  104.8   6.53, s                106.7   6.46, s                109.3   6.59, s                  106.7

  3′                                        149.3                          154.3                          152.0                            153.9

  4′                                        136.4                          139.9                          135.3                            140.1

  5′                                        149.3                          154.3                          152.0                            153.9

  6′               6.80, s                  104.8   6.53, s                106.7   6.60, s                112.1   6.59, s                  106.7

  7′               4.98, d, (9.0)           84.2    2.67, t, (7.5)         33.4    2.56, t, (7.5)         33.0    2.69, t, (7.5)           33.4

  8′               2.45, m,                 51.1    1.86, m                35.4    1.80, m                35.2    1.87, m                  35.4

  9′               3.72, (dd,12.0, 5.0)\    64.8\   3.61, t, (6.4)\        62.8\   3.56, t, (6.5)\        62.2\   3.81, dd, (11.0, 2.5)\   69.2\
                   4.36, overlapped                                                                               3.93, dd, (11.0, 4.0)     

  Glu-1′′          4.36, d, (8.0)           104.6   4.23, d, (7.5)         101.0   4.93, d, (7.5)         103.0   4.32, d, (8.0)           104.5

  Glu-2′′          3.26, overlapped         75.2    3.45, overlapped       75.2    3.48, overlapped       75.1    3.21, overlapped         75.4

  Glu-3′′          3.40, overlapped         78.1    3.45, overlapped       77.8    3.41, overlapped       78.0    3.25, overlapped         77.9

  Glu-4′′          3.33, overlapped         71.6    3.32, overlapped       71.9    3.40, overlapped       71.4    3.26, overlapped         71.8

  Glu-5′′          3.36, overlapped         78.2    3.45, overlapped       78.1    3.47, overlapped       78.3    3.28, overlapped         78.0

  Glu-6′′          4.32, overlapped\        62.8    3.87, overlapped\      62.2    3.68, overlapped\      62.5    3.68, overlapped\        62.9
                   4.36, overlapped                 3.92, overlapped               3.89, overlapped               3.89, overlapped         

  [C]{.ul}OCH~3~                            172.8                                                                                          

  CO[C]{.ul}H~3~   1.95 (3H, s)             20.7                                                                                           

  3-OCH~3~         3.93 (3H, s)             56.9    3.89 (3H, s)           56.4    3.86, (3H, s)          56.4    3.89, (3H, s)            56.5

  5-OCH~3~         3.93 (3H, s)             56.9                                                                                           

  3′-OCH~3~        3.93 (3H, s)             56.9    3.74 (3H, s)           56.4                                   3.89, (3H, s)            56.6

  5′-OCH~3~        3.93 (3H, s)             56.9    3.74 (3H, s)           56.4                                   3.89, (3H, s)            56.6
  ------------------------------------------------------------------------------------------------------------------------------------------------

^a^ Assignments were carried out based on HSQC and HMBC experiments.
